Table 2 Fracture prevention studies that have selected patients using central DXA.

Class of agent	Name of drug	Study name	T‐score thresholds for patient enrolment*
Bisphosphonate	Alendronate	FIT 115	Femoral neck T‐score < −1.5†
		FIT 216	Femoral neck T‐score < −1.5
	Risedronate	VERT NA17	Spine T‐score < −2†
		HIP18	Femoral neck T‐score < −3.2‡
	Ibandronate	BONE19	Spine T‐score in range −2 to −5†
	Zoledronate	HORIZON20	Femoral neck T‐score < −2.5†
Selective estrogen receptor modulator	Raloxifene	MORE21	Spine or femoral neck T‐score < −1.8†
Parathyroid hormone	PTH (1‐34)	Neer study22	Spine or femoral neck T‐score < −1†
Strontium	Strontium ranelate	SOTI23	Spine T‐score < −1.9†
		TROPOS24	Femoral neck T‐score < −2.2

BONE, Oral Ibandronate Osteoporosis vertebral fracture trial in North America and Europe; FIT, Fracture Intervention Trial; HIP, Risedronate Hip Study; HORIZON, HORIZON Pivotal Fracture Trial; MORE, Multiple Outcomes of Raloxifene Evaluation; SOTI, Spinal Osteoporosis Therapeutic Intervention; TROPOS, Treatment of Peripheral Osteoporosis; VERT NA, Vertebral Efficacy with Risedronate Therapy (North America) study

*T‐score thresholds are those calculated using the NHANES III reference range for the hip and the Hologic reference range for spine BMD.⁵²

†Study entry criteria also included prevalent vertebral fractures.

‡Study entry criteria also included clinical risk factors.